JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (7): 73-77.doi: 10.6040/j.issn.1671-7554.0.2015.049

Previous Articles     Next Articles

A feasibility study for boost target delineation using 18F-FDG PET/CT in local advanced non-small cell lung cancer

GAO Ang, WANG Shijiang, FU Zheng, SUN Xindong, YU Jinming, MENG Xue   

  1. Department of Radiation Oncology, Shandong Cancer Hospital; Shandong Academy of Medical Sciences, Jinan 250012, Shandong, China
  • Received:2015-01-13 Revised:2015-04-16 Published:2015-07-10

PDF (PC)

330

Abstract: Objective To evaluate whether during-radiotherapy or post-radiotherapy 18F-FDG uptake locations within tumour can be identified by a pre-radiotherapy scan for non-small cell lung cancer, and to explore the optimal biological sub-volume of the primary tumor for dose escalation. Methods 18F-FDG PET/CT scans were performed at pre-radiotherapy, during-radiotherapy (40 Gy) or post-radiotherapy. The region of interests were auto-delineated using the 40%-70% maximal standardized uptake value (SUVmax) thresholds using pre-radiotherapy scan. Overlap fractions between pre-radiotherapy scan and during-radiotherapy or post-radiotherapy scan were calculated. Then, a Spearman correlation was used to analyze the correlations between the volumes of the region of interests and sensitivities of radiotherapy. Results The 50% SUVmax-delineated region of interests had large overlap fractions with the 40% SUVmax-delineated and manual-delineated regions of high uptake at during-radiotherapy, with the values being (74.3±15.9)% and (84.4±15.3)%, respectively. The overlap fractions of 50% SUVmax-delineated region of interests and the 80% SUVmax-delineated regions of high uptake at post-radiotherapy were more than 72%. The volume of 50% SUVmax-delineated region of interests was smaller than the gross tumor volume (GTV), with the value of being (29.4±12.3)%. However, the 50% SUVmax-delineated region of interests had no correlations with the sensitivities of radiotherapy. Conclusion A 18F-FDG PET/CT scan at pre-radiotherapy can identify the high 18F-FDG uptake regions at during-radiotherapy and post-radiotherapy. The 50% SUVmax-delineated volume may be a suitable region for dose boosting.

Key words: Dose painting, Non-small cell lung cancer, 18F-FDG-PET, Boost target delineation

CLC Number: 

  • R734.2
[1] Machtay M, bae K, Movsas B, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1): 425-434.
[2] Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study[J]. Lancet Oncol, 2015, 16(2): 187-199.
[3] Allal AS, Slosman DO, Kebdani T, et al. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose[J]. Int J Radiat Oncol Biol Phys, 2004, 59(5): 1295-1300.
[4] Aerts HJ, Bosmans G, van Baardwijk AA, et al. Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study[J]. Int J Radiat Oncol Biol Phys, 2008, 71(5): 1402-1407.
[5] Feng M, Kong FM, Gross M, et al. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing[J]. Int J Radiat Oncol Biol Phys, 2009, 73(4): 1228-1234.
[6] Gillham C, Zips D, Pönisch F, et al. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?[J]. Radiother Oncol, 2008, 88(3): 335-341.
[7] van Elmpt W, De Ruysscher D, van der Salm A, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer[J]. Radiother Oncol, 2012, 104(1): 67-71.
[8] Møller DS, Khalil AA, Knap MM, et al. A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients[J]. Acta Oncol, 2011, 50(6): 883-888.
[9] Edet-Sanson A, Dubray B, Doyeux K, et al. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC)[J]. Radiother Oncol, 2012, 102(2): 251-257.
[10] Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
[11] Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding[J]. Cancer, 1997, 80(12 Suppl): 2505-2509.
[12] Black QC, Grills IS, Kestin LL, et al. Defining a radiotherapy target with positron emission tomography[J]. Int J Radiat Oncol Biol Phys, 2004, 60(4): 1272-1782.
[13] 党亚正, 费晋秀.肿瘤乏氧细胞与放射治疗[J].现代肿瘤医学, 2008, 16(3): 492-497.
[14] Yu J, Li X, Xing L, et al. Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study[J]. Int J Radiat Oncol Biol Phys, 2009, 75(5): 1468-1474.
[15] Dubois L, Landuyt W, Cloetens L, et al.[18F]EF3 is not superior to[18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model[J]. Eur J Nucl Med Mol Imaging, 2009, 36(2): 209-218.
[16] Nehmeh SA, Lee NY, Schröder H, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer[J]. Int J Radiat Oncol Biol Phys, 2008, 70(1): 235-242.
[17] Maftei CA, Shi K, Bayer C, et al. Comparison of (immuno-)fluorescence data with serial[(1)(8)F]Fmiso PET/CT imaging for assessment of chronic and acute hypoxia in head and neck cancers[J]. Radiother Oncol, 2011, 99(3): 412-417.
[18] Aerts HJ, Lambin P, Ruysscher DD. FDG for dose painting: a rational choice[J]. Radiother Oncol, 2010, 97(2): 163-164.
[19] Nyflot MJ, Harari PM, Yip S, et al. Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx[J]. Radiother Oncol, 2012, 105(1): 36-40.
[20] van Baardwijk A, Dooms C, van Suylen RJ, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer[J]. Eur J Cancer, 2007, 43(9): 1392-1398.
[21] Van den Bergh L, Isebaert S, Koole M, et al. Does 11C-choline PET-CT contribute to multiparametric MRI for prostate cancer localisation?[J]. Strahlenther Onkol, 2013, 189(9): 789-795.
[22] Alber M, Thorwarth D. Multi-modality functional image guided dose escalation in the presence of uncertainties[J]. Radiother Oncol, 2014, 111(3): 354-359.
[1] SUN Qijing, CHEN Fangfang, LI Chunxiao, ZHANG Caiqing. Clinical value of PNI and HGB in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 55-59.
[2] PENG Yue, FENG Zhen, XIE Hounai, WANG Hui, LI Meng, REN Wangang, LIU Tong, PENG Zhongmin. Surgical treatment for 61 patients with multiple lung lesions [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(11): 42-46.
[3] WANG Lili, HUO Bin, WANG Lei, WANG Hao, HOU Dingkun, HUO Xiaodong, WANG Jinhuan, ZANG Li, CAO Qiang, CHAI Shude, WANG Haitao. Meta-analysis and system evaluation of 125I implantation in the treatment of early lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 76-83.
[4] YANG Lu, LIU Yanguo, LI Jisheng, WANG Xiuwen. Effect of bufalin on chemosensitivity to cisplatin in non-small cell lung cancer and the underlying mechanisms [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(3): 6-11.
[5] GAO Peng, SHEN Fangzhen, XIAO Wenjing, XIU Yuande, ZHOU Lingling. Correlation between the expressions of Runx2 and Ezrin and postoperative metastasis in patients with stage IB non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(1): 63-66.
[6] YUAN Zhiping, MOU Huaping, CHEN Jialian, DENG Li. Expressions and significances of serum hepatic cancer-derived growth factor and vascular endothelial growth factor in patients with non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 63-66.
[7] ALIMUJIANG·Stiwaerdi, ZHANG Tao, PATIGULI·Aerxiding, LIU Li. Clinical analysis of recombinant human endostatin combined with gemcitabine and  cisplatin therapy in advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(3): 95-98.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd